Overview
Biocon Biologics is a fully integrated, global biosimilars player with a unique portfolio of high-quality affordable therapeutics spanning insulins, monoclonal antibodies (mAbs) and conjugated recombinant proteins.
Inspired by our promise of ‘Transforming Healthcare. Transforming Lives’, we leverage cutting-edge science, innovative tech platforms and global-scale manufacturing, to deliver life-changing medicines that lower the burden of care.
Foresight, innovation, and a deep commitment to affordable access, define our biosimilars journey. Way back in 2000, Biocon was perhaps the only Indian company to envision a future transformed by biosimilars. At a time when the world was dependent on expensive innovator biologics, we began building specialized capabilities to make lower-cost, high-quality biosimilar treatment options available.
In 2004, we disrupted the Indian insulin market by launching the world’s first Pichia pastoris technology-based recombinant human insulin (rh-Insulin). This revolutionary insulin uncoupled the monopoly of costly biologics, giving millions of Indians unprecedented access to effective and affordable diabetes therapy. In 2009, we introduced long-acting Insulin Glargine, which over the next decade, was approved and commercialized in markets including the U.S, EU, Japan and Australia. 2021 marked a ground-breaking milestone for Biocon Biologics with our Insulin Glargine becoming the first interchangeable biosimilar in the world to be approved by the U.S. FDA. With the 2022 acquisition and integration of long-term partner Viatris’ global biosimilars business, Biocon Biologics now directly commercializes its products across 120+ markets worldwide.
Today, Biocon Biologics continues to set global benchmarks, extending its expertise to biosimilar mAbs and conjugated recombinant proteins for the treatment of diabetes, cancer, autoimmune diseases, ophthalmic conditions, bone health and other non-communicable disease areas. We have one of the deepest biosimilar pipelines in the industry, an unmatched understanding of the science and regulatory pathways, and continue to invest significant resources in facilities and people. Our strategy of developing core and differentiated R&D and manufacturing capabilities, coupled with a robust commercial network, enables us to deliver lower-cost biologics, better care and greater hope to millions around the world.
Biocon Biologics has established a strong and growing presence in advanced markets in North America (United States & Canada), Europe, and JANZ (Japan, Australia, New Zealand). With a robust portfolio of biosimilars across key therapy areas—diabetes, oncology, and immunology—we have established solid brand equity among customers, partners, and patients as well as built significant market shares in these markets.
The Company also has a strong and growing presence in Emerging Markets (EMs), with a commercial footprint spanning over 80 countries that are home to 70% of the patients we serve. Our self-led and partner/distributor-led commercial models allow us to flexibly navigate diverse market landscapes while maximizing reach and impact in key EM regions, including AFMET (Africa, Middle East, and Turkey), APAC (Asia-Pacific), and LATAM (Latin America).
We are among the world’s Top 15 biomanufacturing companies in terms of capacity, and a leading global insulins producer.
Today, Biocon Biologics continues to set global benchmarks, extending its expertise to biosimilar mAbs and conjugated recombinant proteins for the treatment of diabetes, cancer, autoimmune diseases, ophthalmic conditions, bone health and other vital disease areas. We have one of the deepest biosimilar pipelines in the industry, an unmatched understanding of the science and regulatory pathways, and continue to invest significant resources in facilities and people. Our strategy of developing core and differentiated R&D and manufacturing capabilities, coupled with a robust commercial network, enables us to deliver lower-cost biologics, better care and greater hope to millions around the world.
